or Try an Advanced Search...

    Technical Analysis for OPTN - OptiNose, Inc.

    Grade Last Price % Change Price Change
    F 0.91 -2.19% -0.02
    OPTN closed down 2.19 percent on Thursday, April 25, 2024, on 20.1 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 9
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical OPTN trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Volume Surge Other 0.00%
    Wide Range Bar Range Expansion 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -2.19%
    Older End-of-Day Signals for OPTN ...

       Recent Intraday Alerts

    Alert Time
    Reversed from Up about 15 hours ago
    Gap Up Closed about 15 hours ago
    Down 2 % about 15 hours ago
    Down 1% about 15 hours ago
    10 DMA Resistance about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OPTN Chart by TradingView
    Basic chart:

    Profile

    OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Clinical Medicine Pharmaceutical Disease Organ Systems Inflammation Allergy Respiratory Therapy Polyp Sinus Glucocorticoids Chronic Rhinosinusitis Corticosteroid Nasal Spray Sinusitis Fluticasone Nasal Polyps

    Is OPTN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Apr 25 Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
    Apr 6 OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
    Apr 4 Optinose to Present at the Needham Virtual Healthcare Conference
    Mar 16 OptiNose granted FDA nod to expand labeling for sinusitis therapy
    Mar 15 XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
    Mar 10 US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
    Mar 8 OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript
    Mar 8 OptiNose Full Year 2023 Earnings: EPS Beats Expectations
    Mar 8 Q4 2023 OptiNose Inc Earnings Call
    See more OPTN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.1
    52 Week Low 0.855
    Average Volume 1,161,965
    200-Day Moving Average 1.29
    50-Day Moving Average 1.47
    20-Day Moving Average 1.18
    10-Day Moving Average 1.02
    Average True Range 0.13
    RSI (14) 26.47
    ADX 37.56
    +DI 24.99
    -DI 25.13
    Chandelier Exit (Long, 3 ATRs) 1.19
    Chandelier Exit (Short, 3 ATRs) 1.23
    Upper Bollinger Bands 1.56
    Lower Bollinger Band 0.80
    Percent B (%b) 0.14
    BandWidth 64.19
    MACD Line -0.17
    MACD Signal Line -0.15
    MACD Histogram -0.0206
    Fundamentals Value
    Market Cap 101.64 Million
    Num Shares 112 Million
    EPS -0.38
    Price-to-Earnings (P/E) Ratio -2.38
    Price-to-Sales 2.09
    Price-to-Book 24.26
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.45
    Resistance 3 (R3) 1.50 1.38 1.36
    Resistance 2 (R2) 1.38 1.24 1.35 1.33
    Resistance 1 (R1) 1.14 1.15 1.08 1.09 1.30
    Pivot Point 1.01 1.01 0.98 0.99 1.01
    Support 1 (S1) 0.78 0.88 0.72 0.72 0.51
    Support 2 (S2) 0.65 0.79 0.62 0.48
    Support 3 (S3) 0.42 0.65 0.45
    Support 4 (S4) 0.36